CN1077797C - Chinese medicine powder preparation for curing leukemia - Google Patents
Chinese medicine powder preparation for curing leukemia Download PDFInfo
- Publication number
- CN1077797C CN1077797C CN99124959A CN99124959A CN1077797C CN 1077797 C CN1077797 C CN 1077797C CN 99124959 A CN99124959 A CN 99124959A CN 99124959 A CN99124959 A CN 99124959A CN 1077797 C CN1077797 C CN 1077797C
- Authority
- CN
- China
- Prior art keywords
- grams
- parts
- radix
- chinese medicine
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to traditional Chinese medicinal powder for treating leukemia, which can be used for treating nosohemias, such as aplastic anemia, etc. The medicinal powder is made from bupleurum root, perilla leaf, fineleaf schizonepeta herb, largehead atractylodes rhizome, charred triplet, tuckahoe, ophiopogon, white peony alba, angelica, gardenia, scutellaria, pangolin scale, turtle shell, lower shell, oriental wormwood, common anemarrhena rhizome, wolfberry bark, licorice, imperatae rhizoma and eucommia bark. The present invention has the advantages of scientific and reasonable compatibility, convenient taking, low cost, good therapeutic effect, no side effect and good economic and social benefit.
Description
The present invention relates to a kind of leukemic Chinese medicine powder (claiming Bai Xuekang again) for the treatment of clinically, also can be used for aplastic anemia.
Leukemia is a kind of difficult disease of common pilosity, claims leukemia again.The leukemic medicine of treatment is a lot of at present, but its curative effect is not good enough.Treat leukemic best approach is to carry out bone marrow transplantation for this reason, but its expense costliness, and the difficult again selection of suitable bone marrow, therefore at present still based on Drug therapy, and the dual-purpose chemotherapy.But all curative effect is not good enough, and side effect is arranged, and particularly takes Western medicine and chemotherapy.Therefore, how to adopt medicine effectively to treat leukemia and be still the problem that people are concerned about.
Purpose of the present invention just provides the leukemic Chinese medicine powder of a kind of treatment, to solve the leukemic medication problem of treatment conveniently and effectively.
The object of the present invention is achieved like this, according to the Chinese medicine and pharmacy principle, leukemia belongs to exopathogen stream internal organs, the infringement vital organs of the human body, and hemopoietic function goes down, leukocyte infinitely increases or reduces, make viscera function imbalance, that the health invasion and attack form is hemorrhage, deteriorated blood, warm blood, returns pyretic toxicity to send out a class category, it is purpose that its treatment is adopted to effect a permanent cure, treating both the principal and secondary aspects of a disease.According to the Chinese materia medica principle, adopt Radix Bupleuri, Folium Perillae, Herba Schizonepetae, the Rhizoma Atractylodis Macrocephalae, JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria, Radix Ophiopogonis, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Fructus Gardeniae, Radix Scutellariae, Squama Manis, Carapax Trionycis, Carapax et Plastrum Testudinis (Carapax et Plastrum Testudinis), Herba Artemisiae Scopariae, the Rhizoma Anemarrhenae, Cortex Lycii, Radix Glycyrrhizae, Rhizoma Imperatae, the Cortex Eucommiae to make Chinese medicine powder and get final product.
Compatibility of the present invention is scientific and reasonable, abundant raw materials, and taking convenience safety has no side effect, and good effect is easy to apply, and can be the treatment leukemia and makes positive contribution
Below in conjunction with concrete condition and embodiment the present invention is elaborated.
According to aforementioned medicine requirement, the present invention adopts by weight 15 parts of Radix Bupleuri, 6 parts of Folium Perillae, 9 parts of Herba Schizonepetae, 9 parts of the Rhizoma Atractylodis Macrocephalaes, each 9 parts of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), 15 parts in Poria, 9 parts of Radix Ophiopogonis, 15 parts of the Radix Paeoniae Albas, 15 parts of Radix Angelicae Sinensis, 9 parts of Fructus Gardeniaees, 9 parts of Radix Scutellariae, 6 parts of Squama Maniss, goes up 9 parts of first, 9 parts of Carapax et Plastrum Testudinis, 9 parts of Herba Artemisiae Scopariaes, 9 parts of the Rhizoma Anemarrhenaes, 9 parts of Cortex Lycii, 9 parts in Radix Glycyrrhizae, 6 parts of Rhizoma Imperataes, the Cortex Eucommiae are formed medicine for 9 parts, and it is ground into Chinese medicine part gets final product.
As restraining juice by adult's dose 216 on the one, it is Radix Bupleuri 15 grams, Folium Perillae 6 grams, Herba Schizonepetae 9 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, each 9 gram of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria 15 grams, Radix Ophiopogonis 9 grams, the Radix Paeoniae Alba 15 grams, Radix Angelicae Sinensis 15 grams, Herba Artemisiae Scopariae 9 grams, the Rhizoma Anemarrhenae 9 grams, Cortex Lycii 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Imperatae 6 grams, the Cortex Eucommiae 9 grams, Fructus Gardeniae 9 grams, Radix Scutellariae 15 grams, Squama Manis 6 grams that its Chinese medicine powder constitutes, go up first 9 grams, Carapax et Plastrum Testudinis 9 grams are formed, be crushed and screened into powder through size reduction machinery, restrain the medicated powder decoctions with 216 when taking, the decocting secondary, sooner or later respectively once, each 106 grams, the child can be cut down according to the circumstance on request in this way.If need other dosage, can connect the compatibility requirement, enlarge or dwindle.
The Chinese medicine powder of making by said medicine, as everybody knows, its symptom of leukemia show as more dizziness, ear toot, unable, heating and with hemopoietic function go down, leukocyte infinitely increases or reduce, want to cure this disease, must make hematopoietic function recovery, want to make hematopoietic function recovery, must effect a radical cure the cause of disease, get rid of evils and set upright, and all medicines of its compatibility head it off just in time.In its compatibility, Radix Bupleuri, Folium Perillae, Herba Schizonepetae can prevent superfunction, and exopathogen can not be invaded; The Rhizoma Atractylodis Macrocephalae, JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria can be built taste poker, water channel, Shui Gu, and precise and tiny energyization is given birth to, angry blood; Radix Ophiopogonis, the Radix Paeoniae Alba, Fructus Gardeniae, Radix Scutellariae removing heat from blood, hemopoietic; Squama Manis, Carapax et Plastrum Testudinis, last first depressed liver-energy dispersing and QI regulating; The Radix Angelicae Sinensis blood circulation promoting and blood stasis dispelling, the catharsis function of promotion liver; Herba Artemisiae Scopariae, Radix Glycyrrhizae are annotated jaundice diuretic, antiviral; The Rhizoma Anemarrhenae, Cortex Lycii, the Cortex Eucommiae, Rhizoma Imperatae energy promoting the production of body fluid to quench thirst, cloudy now tonifying YANG, removing heat from blood are gone into kidney, main bone is given birth to marrow.The reasonable cooperation of above-mentioned all medicines can make hemopoietic function, hemopoietic functional rehabilitation normal effectively, increases the resistance against diseases of body, controls leukocytic unlimited increase or minimizing, thereby hematopoietic disorders is removed, and sick body is rehabilitated.Clinical practice has also proved this point.
Through in recent years the situation of 80 routine leukemia human therapies being seen, wherein male 48 people, woman 32 people, age was taken 216 grams every day at 14-68 years old, each decoction 108 gram of per morning and evening, 32 days is a course of treatment, take medicine 1-2 the course of treatment sx, 4-6 the course of treatment transference cure, bone marrow check half a year transfers to normally to half.Took after a course of treatment drug withdrawal 3-7 days at every turn, and continued again to take, after the remission, reduce by half to take and kept curative effect in 3 months.
The present invention also is effectively applied to aplastic anemia, as to 32 people's clinical practices, and wherein male 16 people, women 16 people, the age is 8-68 years old, and consumption is grams every days 216, divides the secondary usefulness that is decocted in water for oral dose, and each 108 grams have all been obtained satisfied effect, and seeing has 1.
Table 1 (leukemia and aplastic anemia joint account)
Experimental group is taken Chinese medicine powder, and matched group is taken Western medicine, and Western medicine includes vincristin, prednisone, gentle red mould etc., finds out that obviously experimental group is better than matched group from table.
Group | The example number | Produce effects | Effectively | Invalid | Total effective rate |
Experimental group | 112 | 80 | 25 | 7 | 94% |
Matched group | 112 | 35 | 38 | 39 | 65.2% |
With regard to its clinical symptoms, obvious difference is arranged all before and after the treatment.
Table 2 is taken Chinese medicine powder and chemotherapy contrast
It can be seen from the table, it is respond well to take medicated powder of the present invention, and obviously is better than matched group.Through laboratory examination, with before and after the Chinese medicine powder treatment significant difference being arranged, show that sb.'s illness took a favorable turn, see Table 3,4.
Experimental group | Insomnia | Emit through often feeling | The joint headache | Fever | Face storehouse color is white | Hyperhidrosis | Dizzy | ||
Before the treatment | 112 | 112 | 55 | 112 | 87 | 63 | 76 | ||
After the treatment | Disappear | 80 | 99 | 45 | 102 | 65 | 57 | 58 | |
Take a turn for the better | 22 | 13 | 8 | 10 | 22 | 6 | 14 | ||
Invalid | 10 | 0 | 2 | 0 | 0 | 0 | 4 | ||
Control changing according to learning the treatment group | Before the treatment | 112 | 84 | 43 | 94 | 76 | 65 | 78 | |
After the treatment | Disappear | 84 | 26 | 28 | 30 | 22 | 48 | 12 | |
Take a turn for the better | 38 | 30 | 11 | 42 | 38 | 11 | 63 | ||
Invalid | 41 | 13 | 4 | 22 | 16 | 6 | 3 |
Blood picture synopsis around before and after the treatment of table 3 disorders of blood
Project | CR standard (alleviating standard fully) | Before the treatment | After the treatment |
HB (hemoglobin) | 100g/L (man) 90g/L (woman) (child) | 50 | 110 |
WBC (numeration of leukocyte) | <10×10 9/L | 22×10 9/L | 7×10 9/L |
Neutrophilic granulocyte | ≥1.5×10 9/L | 1.0×10 9/L | 4×10 9/L |
Lymphocyte | <0.4 | 0.55 | 0.28 |
Platelet | ≥100×10 9/L | 70×10 9/L | 105×10 9/L |
Peripheral blood divides the apoplexy due to endogenous wind leukaemia number | Do not have | Do not have |
Medullary cell is checked synopsis (112 count for each person) before and after table 4 treatment
The cell title | Normal value | Standard deviation | Before the treatment | After the treatment | ||||
Slow grain | Anxious grain | Aplastic anemia | ||||||
The granulocyte system | Myeloblast | 0.64 | 0.33 | 2.4 | 0.63 | |||
Promyelocyte | 1.57 | 0.6 | 0.4 | 6.2 | 1 | 1.6 | ||
Neutrophilic granulocyte | Middle children | 6.49 | 2.04 | 15.2 | 9.2 | 6.98 | ||
Evening is young | 7.9 | 1.97 | 23.2 | 8.6 | 4 | 8.8 | ||
Dried shape nuclear | 23.72 | 3.5 | 44.4 | 6.2 | 26.05 | |||
Leaflet nuclear | 9.41 | 2.92 | 9 | 8.8 | 9.25 | |||
Eosinophilic granulocyte | Middle children | 0.38 | 0.23 | 0.4 | 0.3 | |||
Evening is young | 0.49 | 0.32 | 1 | 0.39 | ||||
Dried shape nuclear | 1.25 | 0.61 | 0.4 | 1.05 | ||||
Leaflet nuclear | 0.86 | 0.61 | 1.6 | 0.76 | ||||
Basophil | Middle children | 0.02 | 0.05 | 0.02 | ||||
Evening is young | 0.06 | 0.07 | 0.2 | 0.05 | ||||
Dried shape nuclear | 0.1 | 0.09 | 0.8 | 0.09 | ||||
Leaflet nuclear | 0.03 | 0.05 | 0.4 | 0.03 | ||||
The erythrocyte system | Pronormoblast | 0.57 | 0.3 | 0.2 | 0.6 | 0.2 | ||
Basophilic erythroblast | 0.29 | 0.41 | 0.2 | 1.4 | 0.27 | |||
Polychromatophilic erythroblast | 7.41 | 1.91 | 0.6 | 21 | 4 | 70 | ||
Normoblast | 10.75 | 2.36 | 19.8 | 11 | 7.68 | |||
The lymphocyte system | Lymphoblast | 0.05 | 0.09 | 0.02 | ||||
Inmature lymphocyte | 0.47 | 0.84 | 0.12 | |||||
Lymphocyte | 22.78 | 7.04 | 0.8 | 10.8 | 59 | 02.8 | ||
Unusual lymphocyte | ||||||||
The mononuclear cell system | Monoblast | 0.01 | 0.04 | 0.01 | ||||
Inmature mononuclear cell | 0.14 | 0.19 | 0.17 | |||||
Mononuclear cell | 3 | 0.88 | 0.4 | 4.8 | 2 | 3.49 | ||
The plasma cell system | Plasmablast | 0.004 | 0.02 | |||||
Proplasmacyte | 0.104 | 0.16 | ||||||
Plasma cell | 0.71 | 0.42 | 0.2 | 1 | 0.68 | |||
Other cell | Skein cell | 0.16 | 0.21 | 0.6 | 2 | 0.27 | ||
Endotheliocyte | 0.05 | 0.09 | ||||||
Phagocyte | 0.03 | 0.09 | 0.07 | |||||
Adipose cell | 0.003 | 0.02 | ||||||
Tissue is bitten the alkali cell | 0.03 | 0.09 | 0.03 | |||||
Tissue is bitten sour cell | 0.004 | 0.03 | ||||||
The not clear-cells of classifying | 0.15 | 0.03 | 0.17 | |||||
Remarks: | This table is with reference to Henan Medical Univ.'s one attached institute cytoscopy normal value standard |
Composition of medicine of the present invention also can not become the direct decoction of powder, also can be processed into capsule or tablet and other dosage forms.
Clearly show that by above-mentioned situation the present invention comprises chemotherapeutic treatment leukemia, having greatly improved property of aplastic anemia with existing medicine, have one's own knack that it is applied and must make creative contribution for the treatment hematopathy.
Claims (2)
1, the leukemic Chinese medicine powder of a kind of treatment is characterized in that this Chinese medicine powder is to be made for 9 parts by 15 parts of Radix Bupleuri, 6 parts of Folium Perillae, 9 parts of Herba Schizonepetae, 9 parts of the Rhizoma Atractylodis Macrocephalaes, each 9 parts of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), 15 parts in Poria, 9 parts of Radix Ophiopogonis, 15 parts of the Radix Paeoniae Albas, 15 parts of Radix Angelicae Sinensis, 9 parts of Fructus Gardeniaees, 9 parts of Radix Scutellariaes, 6 parts of Squama Maniss, 9 parts of last first, 9 parts of Carapax et Plastrum Testudinis, 9 parts of Herba Artemisiae Scopariaes, 9 parts of the Rhizoma Anemarrhenaes, 9 parts of Cortex Lycii, 9 parts in Radix Glycyrrhizae, 6 parts of Rhizoma Imperataes, the Cortex Eucommiae.
2, the leukemic Chinese medicine powder of treatment according to claim 1, the Chinese medicine powder of it is characterized in that Radix Bupleuri 15 grams, Folium Perillae 6 grams, Herba Schizonepetae 9 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, each 9 gram of JIAOSANXIAN (Fructus Crataegi, Fructus Hordei Germinatus, Massa Medicata Fermentata), Poria 15 grams, Radix Ophiopogonis 9 grams, the Radix Paeoniae Alba 15 grams, Radix Angelicae Sinensis 15 grams, Herba Artemisiae Scopariae 9 grams, the Rhizoma Anemarrhenae 9 grams, Cortex Lycii 9 grams, Radix Glycyrrhizae 6 grams, Rhizoma Imperatae 6 grams, the Cortex Eucommiae 9 grams, Fructus Gardeniae 9 grams, Radix Scutellariae 15 grams, Squama Manis 6 grams, go up first 9 grams, first 9 being restrained into 216 grams.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99124959A CN1077797C (en) | 1999-12-30 | 1999-12-30 | Chinese medicine powder preparation for curing leukemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99124959A CN1077797C (en) | 1999-12-30 | 1999-12-30 | Chinese medicine powder preparation for curing leukemia |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1262955A CN1262955A (en) | 2000-08-16 |
CN1077797C true CN1077797C (en) | 2002-01-16 |
Family
ID=5283673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99124959A Expired - Fee Related CN1077797C (en) | 1999-12-30 | 1999-12-30 | Chinese medicine powder preparation for curing leukemia |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1077797C (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1157166A (en) * | 1996-01-25 | 1997-08-20 | 温顺明 | Xuefukang medicine |
CN1217188A (en) * | 1997-11-12 | 1999-05-26 | 赵清涛 | Chinese medicine Baixuekang and its production process |
CN1238956A (en) * | 1998-06-12 | 1999-12-22 | 许世平 | Baixuekang for curing leukemia |
-
1999
- 1999-12-30 CN CN99124959A patent/CN1077797C/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1157166A (en) * | 1996-01-25 | 1997-08-20 | 温顺明 | Xuefukang medicine |
CN1217188A (en) * | 1997-11-12 | 1999-05-26 | 赵清涛 | Chinese medicine Baixuekang and its production process |
CN1238956A (en) * | 1998-06-12 | 1999-12-22 | 许世平 | Baixuekang for curing leukemia |
Also Published As
Publication number | Publication date |
---|---|
CN1262955A (en) | 2000-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1062144C (en) | Yisuishengxue chinese medicine preparation for tonifying marrow and promoting generation of blood | |
CN1562160A (en) | Composite medicine for treating hepatitis B complication | |
CN1062157C (en) | Hepatitis B curing toxin-dissipating pill | |
CN1131053C (en) | Chinese medicine for treating diabetes | |
CN101670011A (en) | Medicament for treating rheumatism and rheumatoid and preparation method thereof | |
CN102357211B (en) | Traditional Chinese medicine composition for curing cancers | |
CN1879841A (en) | A Chinese medicine for treating leukemia | |
CN1140064A (en) | Formula and producing method for lactogenic finger citron oral preparation | |
CN101167932A (en) | Traditional Chinese medicine for treating chronic hepatitis B | |
CN1082376C (en) | Pathogenic factor eliminating and healthy energy supporting anticancer medicine | |
CN112891485B (en) | Traditional Chinese medicine composition for treating neocoronary pneumonia | |
CN1077797C (en) | Chinese medicine powder preparation for curing leukemia | |
CN1293908C (en) | Cancer preventing and curing Chinese medicine of two snakes and Ganoderma Lucidum seu Japonicum | |
CN1385191A (en) | Medicine for treating liver disease | |
CN100396300C (en) | Chinese traditional medicine for treating enteritis and appendicitis, and method for preparing same | |
CN103071079B (en) | Traditional Chinese medicinal composition for treating prurigo nodularis | |
CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
CN101703660B (en) | Anti-aging medicament | |
CN1052914C (en) | Suyuwan pill for curing leucoderma | |
CN111759940B (en) | Pharmaceutical composition for treating sicca syndrome and preparation method and application thereof | |
CN102727749B (en) | Medicine for treating aplastic anemia | |
CN1562229A (en) | Formula of Chinese herbal medicine decoction distinguished from males and females and combined with Western medicine for curing hepatitis B | |
CN111214584B (en) | Traditional Chinese medicine composition for tonifying kidney and benefiting liver as well as preparation method and application thereof | |
CN100457177C (en) | Chinese medicinal health-care preparation for cloaring lung, supplementing kidney | |
CN105770815A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition for treating postpartum collapse and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |